目的:观察促性腺激素释放激素激动药联合雌二醇与醋酸甲羟孕酮治疗子宫内膜异位症的临床疗效及安全性。方法:将64例子宫内膜异位症患者随机均分为试验组与对照组。对照组患者服用促性腺激素释放激素激动药,试验组患者在对照组的基础上联合服用雌二醇与醋酸甲羟孕酮。治疗3个月后,比较两组患者的疗效和安全性。结果:治疗后,试验组与对照组患者总有效率分别是100.0%和87.5%,试验组显著高于对照组(P<0.05)。两组患者的血清雌二醇、卵泡刺激素、钙素水平、各项疼痛评分及Kupperman评分与治疗前比较均有显著改善(P<0.05);治疗后,试验组患者的血清雌二醇与钙素水平显著高于对照组(P<0.05),而血清卵泡刺激素水平、潮热出汗评分及骨与关节痛评分显著低于对照组患者(P<0.05)。两组患者均未见严重不良反应发生。结论:促性腺激素释放激素激动药联合雌二醇与醋酸甲羟孕酮治疗子宫内膜异位症疗效显著,且安全性较好。 Objective: To observe the clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with estradiol and medroxyprogesterone acetate in the treatment of endometriosis. Methods: 64 cases of endometriosis were randomly divided into experimental group and control group. Control group patients taking gonadotropin-releasing hormone agonist, test group patients in the control group based on the combination of estradiol and medroxyprogesterone acetate. After 3 months of treatment, the efficacy and safety of the two groups were compared. Results: After treatment, the total effective rate was 100.0% in the test group and 87.5% in the control group, which was significantly higher in the experimental group than in the control group (P <0.05). Serum estradiol, follicle stimulating hormone, calcium levels, pain scores and Kupperman scores in both groups were significantly improved compared with those before treatment (P <0.05). After treatment, the serum estradiol and (P <0.05). Serum follicle stimulating hormone levels, hot flashes sweat scores and bone and joint pain scores were significantly lower than those in the control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion: Gonadotropin-releasing hormone agonist combined with estradiol and medroxyprogesterone acetate in the treatment of endometriosis has significant effect and is safe.